
1. clin infect dis. 1996 oct;23(4):718-22.

clindamycin/primaquine prophylaxis pneumocystis carinii pneumonia.

barber ba(1), pegram ps, high kp.

author information: 
(1)department internal medicine, bowman gray school medicine wake forest
university, winston-salem, north carolina 27157-1042, usa.

the records 206 patients advanced infection due human immunodeficiency
virus type 1 receiving prophylaxis clindamycin/primaquine (c/p),
trimethoprim-sulfamethoxazole (tmp-smz), dapsone prevent pneumocystis
carinii pneumonia (pcp) retrospectively examined. two hundred sixty-two
patient-years prophylaxis accrued (176.2 tmp-smz, 63.4 dapsone, and
22.8 c/p). rates pcp tmp-smz, dapsone, c/p groups 3.4, 
11.0, 30.7 per 100 patient-years, respectively. pairwise comparisons showed
c/p less effective tmp-smz (relative risk [rr], 9.02; 95% confidence
interval [ci], 3.03-26.83). similar trend apparent c/p vs. dapsone (rr,
2.78; 95% ci, 0.98-7.93). receiving primary prophylaxis were
analyzed, c/p recipients remained greater risk tmp-smz recipients (rr,
13.19; 95% ci, 3.54-49.12) dapsone recipients (rr, 3.85; 95% ci, 1.12-13.31).
failure c/p prophylaxis could due, least part, underdosing
(clindamycin, 300 mg/d; primaquine, 15 mg/d). c/p recipients nonspecific
diarrhea tmp-smz recipients (rr, 2.99; 95% ci, 1.61-5.55).

doi: 10.1093/clinids/23.4.718 
pmid: 8909833  [indexed medline]

